Luigi Tordelli Ruda

Dr. Luigi Tordelli Ruda

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Terenzio CosioTerenzio Cosio
Terenzio Cosio
NPNATALIA PEDRETTI
NATALIA PEDRETTI
Luca SpaggiariLuca Spaggiari
Luca Spaggiari
LRLuigi Tordelli Ruda
Luigi Tordelli Ruda
Samyr KennoSamyr Kenno
Samyr Kenno
EPEva Pericolini
Eva Pericolini
Thermo-tolerance is a virulence factor responsible for the emergence of new fungal pathogens, including Candidozyma auris (formerly classified as Candida auris, C. auris). It has been shown that in C. auris the thermo-tolerance, as well as other virulence traits, such as the ability to aggregate, to form pseudo-hyphae, or to produce melanin are strain-specific features. Here, we investigated the impact of different temperatures (25 °C, 37 °C and 42 °C) on the phenotypic and virulence profile of C. auris strain CDC B11903. The results show a positive correlation between the resistance to antifungals and increasing temperature from 25 °C to 37 °C, while no differences were observed between 37 °C and 42 °C, except for Anidulafungin. Furthermore, C. auris growth was impaired at 25 °C as compared to 37 °C and 42 °C. Except for the haemolytic activity, which increased with rising temperatures, phospholipase, lipase and biofilm production were found at all tested temperatures. Moreover, the ability to produce melanin was observed only at 37 °C and 42 °C. The capacity to grow as pseudo-hyphae or in clusters and to adhere to both biotic and abiotic surfaces were observed at all the temperatures tested, with increased propensity of C. auris to adhere to abiotic surfaces with rising temperatures. The results underline the thermo-tolerance of C. auris strain B11903 and its increased virulence profile at human body temperature both in physiological (37 °C) and febrile state (42 °C).

21 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Terenzio CosioTerenzio Cosio
Terenzio Cosio
NPNATALIA PEDRETTI
NATALIA PEDRETTI
Luca SpaggiariLuca Spaggiari
Luca Spaggiari
LRLuigi Tordelli Ruda
Luigi Tordelli Ruda
Samyr KennoSamyr Kenno
Samyr Kenno
EPEva Pericolini
Eva Pericolini
Thermo-tolerance is a virulence factor responsible for the emergence of new fungal pathogens, including Candidozyma auris (formerly classified as Candida auris, C. auris). It has been shown that in C. auris the thermo-tolerance as well as other virulence traits such as the ability to aggregate, to form pseudo-hyphae, or to produce melanin are strain-specific features. Here, we investigated the impact of different temperatures (25 °C, 37 °C and 42 °C) on the phenotypic and virulence profile of C. auris strain CDC B11903. The results show a positive correlation between the resistance to antifungals and increasing temperature from 25 °C to 37 °C, while no differences were observed between 37 °C and 42 °C, except for Anidulafungin. Furthermore, C. auris growth was impaired at 25 °C as compared to 37 °C and 42 °C. Except for the haemolytic activity, which increased with rising temperatures, no significant differences in phospholipase and biofilm production were found at all tested temperatures. Moreover, the ability to produce melanin and lipases were ob-served only at 37 °C and 42 °C. The capacity to grow as pseudo-hyphae or in clusters and to ad-here to both biotic and abiotic surfaces were observed at all the temperatures tested, with in-creased propensity of C. auris to adhere to abiotic surfaces with rising temperatures. The results underline the thermo-tolerance of C. auris strain B11903 and its increased virulence profile at human body temperature both in physiological (37 °C) and febrile state (42 °C).

14 August 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
CPChiara Papalini
Chiara Papalini
GBGiulia Bicchieraro
Giulia Bicchieraro
LRLuigi Tordelli Ruda
Luigi Tordelli Ruda
AWAlicia Yoke Wei Wong
Alicia Yoke Wei Wong
CBClaudia Battistelli Battistelli
Claudia Battistelli Battistelli
Samuele SabbatiniSamuele Sabbatini
Samuele Sabbatini
New beta-lactam/beta-lactamase inhibitor combinations (BL/BLICs) are licensed for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) infections. However, data regarding their efficacy against bacterial biofilms and the potential of synergistic combinations remain limited. This study evaluated their efficacy on planktonic and biofilm forms of KPC-Kp isolated from catheter-related bloodstream infections (CRBSIs), correlating findings with genomic and clinical data. Twelve KPC-3-harboring isolates (ST512, n = 7; ST307, n = 3; ST101, n = 2) were characterized via whole-genome sequencing. Ceftazidime/avibactam (CAZ/AVI), meropenem/vaborbactam (MEM/VAB), and imipenem/relebactam (IMI/REL) were tested alone or combined with fosfomycin (FOS), cefepime (FEP), meropenem (MEM), or imipenem (IMI) using checkerboard assays. All BL/BLICs alone showed significant, comparable efficacy against biofilm-producing strains. However, combination testing revealed heterogeneous synergistic profiles. CAZ/AVI combined with MEM, IMI, or FEP achieved 100% synergy in both planktonic and biofilm states. MEM/VAB-based combinations demonstrated consistent synergy (50–100%), whereas IMI/REL showed higher synergistic rates in biofilm than in planktonic forms. Conversely, FOS-based regimens were significantly less effective against biofilms. These findings provide a clinical rationale for selecting optimized dual regimens to eradicate biofilms, offering a critical therapeutic strategy to preserve vascular devices when catheter removal is unfeasible.